• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Pear Therapeutics

Data backs Pear Therapeutics digital therapeutic for opioid use disorder

June 14, 2022 By Sean Whooley

Pear Therapeutics (Nasdaq:PEAR) today shared real-world data highlighting low costs with its reSET-O prescription digital therapeutic (PDT). Boston-based Pear Therapeutics’ reSET-O represents the only FDA-authorized PDT for the treatment of opioid use disorder (OUD). Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Clinical Trials, Digital Health, Health Technology, Neurological, Patient Monitoring, Software / IT Tagged With: Pear Therapeutics

Pear Therapeutics reports positive real-world data for chronic insomnia treatment

June 8, 2022 By Sean Whooley

Pear Therapeutics (Nasdaq:PEAR) today announced real-world data from a trial of its Somryst prescription digital therapeutic (PDT). Data showed that Somryst, the only FDA-authorized PDT for treating chronic insomnia, achieved significant reductions in symptoms of insomnia, anxiety and depression severity both immediately following treatment and at six-months follow-up. Get the full story at our sister site, […]

Filed Under: Clinical Trials, Digital Health, Health Technology, Neurological, Software / IT Tagged With: Pear Therapeutics

Digital therapeutics open up new opportunities in medicine

May 5, 2022 By Sean Whooley

A wide range of companies are aiming to make waves through digital therapeutic offerings, and each is doing things differently. “We are seeing tremendous momentum for the DTx industry, with more and more products coming to market and gaining commercial coverage and recent signals from the White House and Congress demonstrating their interest and recognition […]

Filed Under: Business/Financial News, Digital Health, Health Technology, Neurological, Software / IT Tagged With: Better Therapeutics, DarioHealth Corp, Digital therapeutics, Pear Therapeutics, Sanofi

FDA grants STeP designation for Pear Therapeutics’ neurobehavioral digital therapeutic

April 13, 2022 By Sean Whooley

Pear Therapeutics (Nasdaq:PEAR) announced today that it received STeP designation from the FDA for its Pear-010 product candidate. Boston-based Pear Therapeutics designed its Pear-010 prescription digital therapeutic (PDT) candidate to provide a neurobehavioral intervention (virtual reality-delivered pain reduction) to patients 18 and older with acute postoperative and acute postprocedural pain. The company said in a […]

Filed Under: Digital Health, Featured, Food & Drug Administration (FDA), Health Technology, Neurological, Regulatory/Compliance, Software / IT Tagged With: FDA, Pear Therapeutics

Pear Therapeutics launches program to offer digital therapeutics through telehealth platforms

April 4, 2022 By Sean Whooley

Pear Therapeutics (Nasdaq:PEAR) announced today that it launched a program to offer digital therapeutic users access to a telehealth provider. Boston-based Pear’s program offers patients seeking treatment for substance use disorder (SUD) or opioid use disorder (OUD) access to a telehealth provider through its “find a provider tool,” as well as in-person care options. Get the […]

Filed Under: Big Data, Business/Financial News, Digital Health, Drug-Device Combinations, Health Technology, Software / IT Tagged With: Pear Therapeutics, PursueCare

Pear Therapeutics posts massive Q4 revenue uptick as product sales increase

March 28, 2022 By Sean Whooley

Pear Therapeutics (Nasdaq:PEAR) missed Wall Street’s fourth-quarter revenue projections despite a major year-over-year increase in sales. The Boston-based prescription digital therapeutic (PDT) developer posted profits of $18.8 million, or 13¢ per share, on sales of $1.2 million for the three months ended Dec. 31, 2021, for a massive bottom-line gain from losses of nearly $48 […]

Filed Under: Business/Financial News, Digital Health, Drug-Device Combinations, Featured, Health Technology, MassDevice Earnings Roundup, Software / IT, Wall Street Beat Tagged With: Pear Therapeutics

Pear Therapeutics joins Epic App Orchard to enable monitoring of its digital therapeutics

March 24, 2022 By Sean Whooley

Pear Therapeutics (Nasdaq:PEAR) announced today that its PearConnect platform is now available in the Epic App Orchard Gallery. By making PearConnect available to healthcare providers through the Epic App Orchard Gallery, the providers who implement the application will be able to access PearConnect within Epic’s leading electronic health record (EHR) platform, allowing them to monitor patients […]

Filed Under: Big Data, Business/Financial News, Digital Health, Drug-Device Combinations, Electronic Medical Records (EMR), Featured, Health Technology, Neurological, Software / IT Tagged With: Pear Therapeutics

Pear Therapeutics to develop digital therapeutic for sleep/wake disorder in Japan

March 21, 2022 By Sean Whooley

Pear Therapeutics (Nasdaq:PEAR) announced today that it entered an agreement to develop a Japanese-language digital therapeutic. Boston-based Pear struck a deal with SoftBank, a Japan-based communication and information technology service provider, to develop the digital therapeutic for the treatment of sleep/wake disorders on the Japanese market. Get the full story at our sister site, Drug Delivery […]

Filed Under: Business/Financial News, Digital Health, Health Technology, Neurological, Software / IT Tagged With: Pear Therapeutics

Pear Therapeutics says new data backs its prescription digital therapeutic for insomnia

March 15, 2022 By Sean Whooley

Pear Therapeutics (Nasdaq:PEAR) today announced data from two studies that highlight the effectiveness of its chronic insomnia treatment. Boston-based Pear Therapeutics designed its Somryst prescription digital therapeutic (PDT) to address the underlying issues of chronic insomnia by delivering cognitive behavioral therapy for insomnia (CBTi), training the body to sleep. The nine-week PDT can be used on […]

Filed Under: Clinical Trials, Digital Health, Featured, Health Technology, Software / IT Tagged With: Pear Therapeutics

Pear Therapeutics advances in efforts to get CMS to cover prescription digital therapeutics

February 28, 2022 By Sean Whooley

Pear Therapeutics (NSDQ:PEAR) announced that the Centers for Medicare & Medicaid Services (CMS) established new coding relevant to its prescription digital therapeutics (PDTs). CMS established a new Level II Healthcare Common Procedure Coding System (HCPCS) code to describe prescription digital behavioral therapy — FDA-cleared — per course of treatment, which extends to PDTs including Pear’s reSET, […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Health Technology, Medicare, News Well, Software / IT Tagged With: Centers for Medicare and Medicaid Services (CMS), CMS, Pear Therapeutics

Pear Therapeutics closes SPAC merger, lists on Nasdaq

December 6, 2021 By Sean Whooley

Pear Therapeutics today began trading on the Nasdaq market following the completion of a previously announced merger at the end of last week. Boston-based Pear confirmed in June that it would go public by merging Thimble Point Acquisition Corp., a special purpose acquisition company (SPAC). Following approval from Thimble Point’s stockholders at the end of […]

Filed Under: Business/Financial News, Digital Health, Featured, Funding Roundup, Health Technology, Initial Public Offering (IPO), MassDevice Earnings Roundup, Software / IT, Wall Street Beat Tagged With: Pear Therapeutics

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS